Kivitz, Alan J. http://orcid.org/0000-0002-1045-1310
Kremer, Joel M.
Legerton, Clarence W. III
Pricop, Luminita
Singhal, Atul
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Article History
Received: 27 June 2023
Accepted: 13 March 2024
First Online: 16 April 2024
Declarations
:
: Alan J. Kivitz has received consultancy fees from AbbVie, Boehringer Ingelheim, Flexion, Gilead, Janssen, Pfizer, Regeneron, Sanofi, and Sun Pharma; has received speaker fees from AbbVie, Celgene, Flexion, Genzyme, GSK, Merck, Novartis, Pfizer, Sanofi, and UCB; and has stock ownership in Amgen, Gilead, GSK, Novartis, Pfizer, and Sanofi. Joel. M. Kremer is a consultant for AbbVie, Amgen, Bristol Myers Squibb, Genentech, Lilly, Pfizer, Regeneron, and Sanofi and has received research grants from AbbVie, Genentech, Lilly, Novartis, and Pfizer. Clarence W. Legerton III has received research grants from AbbVie, Amgen, Astra Zeneca, Biogen, Bristol Myers Squibb, CorEvitas, Eli Lilly, Gilead, GSK, Horizon, Janssen, Scipher, and UCB. Luminita Pricop is an employee and stockholder of Novartis. Atul Singhal has received research/clinical trial grants from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Fujifilm, Gilead, Janssen, Lilly, Mallinckrodt, MedImmune, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB and has participated in a speakers bureau for AbbVie.
: The primary studies were done in accordance with the principles delineated in the Declaration of Helsinki. Patients provided written informed consent before study-related procedures. All included studies were approved by each central institutional review board. Approval was also obtained from the ethics review boards of each additional center that participated in the individual studies.